U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H37N5O10.H2O4S
Molecular Weight 581.592
Optical Activity UNSPECIFIED
Defined Stereocenters 15 / 15
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BEKANAMYCIN SULFATE

SMILES

OS(O)(=O)=O.[H][C@]3(O[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O[C@@]2([H])O[C@H](CO)[C@@H](O)[C@H](N)[C@H]2O)[C@H]1O)O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N

InChI

InChIKey=YGTPKDKJVZOVCO-KELBJJLKSA-N
InChI=1S/C18H37N5O10.H2O4S/c19-2-6-11(26)12(27)9(23)17(30-6)32-15-4(20)1-5(21)16(14(15)29)33-18-13(28)8(22)10(25)7(3-24)31-18;1-5(2,3)4/h4-18,24-29H,1-3,19-23H2;(H2,1,2,3,4)/t4-,5+,6+,7+,8-,9+,10+,11+,12+,13+,14-,15+,16-,17+,18+;/m0./s1

HIDE SMILES / InChI

Molecular Formula H2O4S
Molecular Weight 98.078
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C18H37N5O10
Molecular Weight 483.5139
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 15 / 15
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Sources: www.drugfuture.com/mt/bekanamycin-sulfate.pdf
Curator's Comment: description was created based on several sources, including: http://www.drugfuture.com/chemdata/Kanamycin.html https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000902_022729_FI.pdf&retry=0&sys=m0b1l3

Bekanamycin is an aminoglycoside and is a congener of kanamycin. It is given topically as the sulfate for the treatment of eye infections. It is reported to be more toxic than kanamycin A. Antibiotic complex produced by Streptomyces kanamyceticus Okami & Umezawa from Japanese soil. There are no known interactions with other drugs.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
180.0 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Visucloben antibiotico

Approved Use

It is used in the treatment of eye infections.
PubMed

PubMed

TitleDatePubMed
[Comparative studies on the problem of nephrotoxicity of the aminoglycosides: kanamycin, amikacin, butirosin and kanendomycin].
1976
In vitro and in vivo susceptibility of atypical mycobacteria to various drugs.
1981 Sep-Oct
Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production.
1993 Sep 24
Antimycobacterial activity of phorbol esters from the fruits of Sapium indicum.
2003 Apr
In vitro and in vivo activities of ruthenium(II) phosphine/diimine/picolinate complexes (SCAR) against Mycobacterium tuberculosis.
2013
Patents

Patents

Sample Use Guides

In Vivo Use Guide
One drop 4 times per day
Route of Administration: Other
B. subtilis 168 (strain I) and S. epidermidis ATCC 12228 (strain X) are both susceptible to Bekanamycin (MIC = 4 ug/mL and 0.5 ug/mL, respectively).
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:25:54 GMT 2023
Edited
by admin
on Fri Dec 15 15:25:54 GMT 2023
Record UNII
KB71EA86HM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BEKANAMYCIN SULFATE
MART.   WHO-DD  
Common Name English
NSC-757787
Code English
BEKANAMYCIN SULFATE [MART.]
Common Name English
KANAMYCIN B SULFATE
MI  
Common Name English
BEKANAMYCIN SULPHATE
Common Name English
KANAMYCIN B SULFATE [MI]
Common Name English
KANAMYCIN B SULPHATE
Common Name English
Bekanamycin sulfate [WHO-DD]
Common Name English
BEKANAMYCIN SULFATE [JAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C2363
Created by admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
Code System Code Type Description
MESH
C001495
Created by admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
PRIMARY
NSC
757787
Created by admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
PRIMARY
FDA UNII
KB71EA86HM
Created by admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
PRIMARY
SMS_ID
100000084993
Created by admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
PRIMARY
EVMPD
SUB00687MIG
Created by admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
PRIMARY
CAS
70550-99-1
Created by admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
SUPERSEDED
PUBCHEM
636396
Created by admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
PRIMARY
CHEBI
31255
Created by admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
PRIMARY
EPA CompTox
DTXSID8048739
Created by admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
PRIMARY
CAS
29701-07-3
Created by admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
PRIMARY
MERCK INDEX
m6599
Created by admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL2105594
Created by admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
PRIMARY
NCI_THESAURUS
C76153
Created by admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY